Canada markets closed

FS KKR Capital Corp. II (FSKR)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
20.52-0.10 (-0.48%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Moore Kuehn Encourages TLND, FSKR, BMTC, and MOTN Investors to Contact Law Firm
    GlobeNewswire

    Moore Kuehn Encourages TLND, FSKR, BMTC, and MOTN Investors to Contact Law Firm

    NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Talend S.A. (NASDAQ: TLND) Talend has agreed to be acquired by affiliates of Thoma Bravo, L.P. Under the proposed transaction, shareholders of Talend will receive $66.00 per share. FS KKR Capital Corp. II (NYSE: FSKR) FS KKR Capital Corp. II (“FSKR”) has agreed to merge with FS KKR Capital Corp. (“FSK”). Under the proposed transaction, FSKR shareholders will receive a number of FSK shares with a net asset value per share (“NAV”) equal to the NAV of the FSKR shares they hold. Bryn Mawr Bank Corporation (NASDAQ: BMTC) Bryn Mawr Bank Corporation has agreed to be acquired by WSFS Financial Corporation. Under the proposed transaction, shareholders of Bryn Mawr Bank will receive 0.90 shares of WSFS per share. Motion Acquisition Company (NASDAQ: MOTN) Motion Acquisition Company has agreed to merge with DocGo. Under the proposed transaction, Motion Acquisition shareholders will own just 10% of the combined company. Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts:Moore Kuehn, PLLCJustin Kuehn, Esq.30 Wall Street, 8th FloorNew York, New York 10005jkuehn@moorekuehn.com(212) 709-8245

  • SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of FS KKR Capital Corp. II Merger
    GlobeNewswire

    SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of FS KKR Capital Corp. II Merger

    WILMINGTON, Del., March 10, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating FS KKR Capital Corp. II (“FSKR”) (NYSE: FSKR) regarding possible breaches of fiduciary duties and other violations of law related to FSKR’s agreement to merge with FS KKR Capital Corp. (“FSK”) (NYSE: FSK). To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-fs-kkr-capital-corp-ii. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242 (Toll Free)(302) 295-5310Fax: (302) 654-7530info@rl-legal.com https://rl-legal.com

  • GlobeNewswire

    Chiasma Announces Planned Transition of Former CEO

    Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent phased launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced that Mark Fitzpatrick intends to step down as President and Principal Financial Officer. The company plans to initiate an executive search to identify Mr. Fitzpatrick’s successor.